Two new biotech drugs for colorectal cancer, Avastin and Erbitux
March 2004
Two new biotech drugs for colorectal cancer, Avastin and Erbitux, are making news.
Avastin (bevacizumab) is the first of a new kind...an angiogenesis inhibitor. It slows the growth of blood vessels that tumors need to grow.
It's approved for metastatic colorectal cancer...in combination with traditional chemotherapy. Avastin slows progression...and improves survival by about 5 months.
Get concise advice on drug therapy, plus unlimited access to CE
Pharmacist's Letter membership benefits include:
- 12 issues every year — what you need to know and do, right now
- Quick, practical reference charts and tools
- Comprehensive CE library to meet license renewal and state requirements
- Multiple course formats including live webinars, podcasts, and CE-in-the-Letter to match your learning style
- Plus much more!
Choose the right tier for your needs today.
Already a subscriber? Log in
Volume pricing available. Get a quote